Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 2, 2009, Pages 383-387

  Kolve, Hedwig ^a   Ahlke, Elvira ^a   Fegeler, Wolfgang ^a   Ritter, Jörg ^a   Jürgens, Heribert ^a   Groll, Andreas H ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Antifungal agents; Cancer; Children; Mycoses; Stem cell transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B LIPID COMPLEX; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; CYCLOSPORIN A; NITROGEN; POLYPEPTIDE ANTIBIOTIC AGENT; TACROLIMUS; UREA;

ADOLESCENT; ADULT; ANAPHYLAXIS; ARTICLE; BONE MARROW DEPRESSION; CANDIDEMIA; CHILD; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FEMALE; GRANULOCYTOPENIA; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTIOCYTOSIS X; HUMAN; INFECTION PREVENTION; INJECTION SITE REACTION; KIDNEY DISEASE; LIVER DISEASE; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MYCOSIS; OVERALL SURVIVAL; PEDIATRICS; SIDE EFFECT; SOLID TUMOR; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL;

ADOLESCENT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; MALE; MYCOSES; NEOPLASMS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67650961323     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp196     Document Type: Article

References (24)

1. Steinbach WJ, Walsh TJ. Mycoses in pediatric patients. Infect Dis Clin North Am 2006; 20: 663-78.
2. Chiou CC, Walsh TJ, Groll AH. Clinical pharmacology of antifungal agents in pediatric patients. Expert Opin Pharmacother 2007; 8: 2465-89.
3. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: A phase III randomised double-blind trial. Lancet 2007; 369: 1519-27.
4. Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289-97.
5. Prentice HG, Hann IM, Herbrecht R et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98: 711-8.
6. Ringden O, Andstrom EE, Remberger M et al. Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bonemarrow transplantation. Pediatr Transplant 1997; 1: 124-9.
7. Maertens J, Madero-Lopez L, Reilly A et al. A randomized, double-blind, multicenter trial of caspofungin versus liposomal amphotericin B for empirical antifungal therapy of pediatric patients with persistent fever and neutropenia. In: Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007. Abstract M-621, p. 435. American Society for Microbiology, Washington DC, USA.
8. Queiroz-Telles F, Berezin E, Leverger G et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: Substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008; 27: 820-6.
9. Walsh TJ, Shad A, Bekersky I et al. Safety, tolerability and pharmacokinetics of liposomal amphotericin B in immunocompromised pediatric patients. In: Abstracts of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2008. Abstract A-005, p. 2. American Society for Microbiology, Washington DC, USA.
10. U. S. Food and Drug Administration Center for Drug Evaluation and Research. Common Terminology Criteria for Adverse Events (CTCAE) v3.0; http://www.fda.gov/cder/cancer/toxicityframe.htm (8 March 2009, date last accessed).
11. Ascioglu S, Rex JH, de Pauw B et al. Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7-14.
12. Maertens J, Raad I, Petrikkos G et al. Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-71.
13. Kartsonis NA, Saah A, Lipka CJ et al. Second-line therapy with caspofungin for mucosal or invasive candidiasis: Results from the caspofungin compassionate-use study. J Antimicrob Chemother 2004; 53: 878-81.
14. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-71.
15. Walsh TJ, Adamson PC, Seibel NL et al. Pharmacokinetics of caspofungin in pediatric patients. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract M-896, p. 395. American Society for Microbiology, Washington DC, USA.
16. Walsh TJ, Arguedas A, Driscoll T et al. Pharmacokinetics of intravenous voriconazole in children after single and multiple dose administration. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001. Abstract A-17, p. 2. American Society for Microbiology, Washington DC, USA.
17. Groll AH, Gea-Banacloche JC, Glasmacher A et al. Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 2003; 17: 159-91.
18. Fischer MA, Winkelmayer WC, Rubin RH, Avorn J. The hepatotoxicity of anti-fungal medications in bone marrow transplant recipients. Clin Infect Dis 2005; 41: 1-7.
19. Johnson MD, Drew RH, Perfect JR. Chest discomfort associated with liposomal amphotericin B: Report of three cases and review of the literature. Pharmacotherapy 1998; 8: 1053-61.
20. Roden MM, Nelson LD, Knudsen TA et al. Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics. Clin Infect Dis 2003; 36: 1213-20.
21. Laing RB, Milne LJ, Leen CL et al. Anaphylactic reactions to liposomal amphotericin. Lancet 1994; 344: 682.
22. Ringden O, Andström E, Remberger M et al. Allergic reactions and other rare side-effects of liposomal amphotericin. Lancet 1994; 344: 1156-7.
23. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
24. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-92.